On March 6, 2018 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small-molecule drugs that address cancer, liver disease and inflammatory diseases, reported that it will be presenting at the 30th Annual ROTH Conference, being held on March 11-14, 2018 in Dana Point, California and participate in a NASH panel discussion titled "News is Great, Novel is Better (Press release, Can-Fite BioPharma, MAR 6, 2018, View Source [SID1234524440])".

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Panel discussions on the latest topics and developments in NASH/PBC drug development span two days at the Roth Conference and are slated to feature 20 public and private companies in the field of liver diseases, 8renowned Key Opinion Leaders, 3 NASH/PBC patients, and The American Liver Foundation.

In addition, Dr. Fishman will deliver the Company’s corporate presentation and provide updates on its lead drug candidate, Piclidenoson (CF101), currently in a Phase III trial for rheumatoid arthritis and is expected to enter a Phase III trial for psoriasis during 2018. The Company’s liver drug Namodenoson (CF102) is in a Phase II trial for patients with advanced liver cancer and is in a Phase II trial for the treatment of NAFLD/NASH.

The company recently provided an update on the progress of its ongoing Phase II NASH study and anticipates the completion of patient enrollment toward the end of 2018 and data release in the first half of 2019.

There is currently no U.S. FDA approved drug for the treatment of NASH, which is an addressable pharmaceutical market estimated to reach $35-40 billion by 2025.

On March 6, 2018 Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), reported that it will present at the 30th Annual Roth conference taking place on March 11-13 at The Ritz Carlton Hotel in Dana Point, California (Press release, Onconova, MAR 6, 2018, View Source [SID1234524458]). The Company’s Chief Medical Officer, Dr. Steven Fruchtman, will present and be available for one-on-one meetings.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details:

Date: Monday, March 12th, 2018

Time: 7:00 am PT

Location: The Ritz Carlton in Dana Point, Salon 6

The presentation will be available here on the Company’s website.

On March 6, 2018 -Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle) product platform, reported that Kevin Lee, Ph.D., Bicycle’s Chief Executive Officer, will present a company overview at the Cowen and Company 38th Annual Health Care Conference in Boston, Mass (Press release, Bicycle Therapeutics, JUN 6, 2018, View Source [SID1234524526]). The presentation will take place at 4:30 p.m. on Tuesday, March 13, 2018 at The Boston Marriott Copley Place.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

on March 6, 2018 argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, reported that its Chief Executive Officer, Tim Van Hauwermeiren, will present on Tuesday, March 13th at 10:40 a.m. ET at the Cowen and Company 38th annual Health Care Conference in Boston (Press release, , JUN 6, 2018, View Source [SID1234524625]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on the argenx’s website at www.argenx.com. Replays of the webcasts will be available for 90 days following the presentation.

Tetraphase has filed a 10-K – Annual report [Section 13 and 15(d), not S-K Item 405] with the U.S. Securities and Exchange Commission (Filing, 10-K, Tetraphase, 2018, MAR 6, 2018, View Source [SID1234524428]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!